ETF Target Price Analysis: The T. Rowe Price Capital Appreciation Equity ETF (TCAF) has an implied analyst target price of $45.05, indicating an 18.20% upside from its current trading price of $38.11.
Notable Holdings with Upside: Key underlying holdings of TCAF, such as Vaxcyte Inc (PCVX), Workday Inc (WDAY), and Danaher Corp (DHR), show significant potential for price increases based on analyst targets, with PCVX having a target 135.29% higher than its current price.
Market Sentiment and Analyst Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent market developments.
Investor Research Importance: Investors are encouraged to conduct further research to assess the validity of analyst targets and their implications for future stock performance.
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 240.080
Low
235.00
Averages
261.57
High
310.00
Current: 240.080
Low
235.00
Averages
261.57
High
310.00
TD Cowen
Buy
maintain
$260 -> $270
2026-01-07
Reason
TD Cowen
Price Target
$260 -> $270
AI Analysis
2026-01-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Danaher to $270 from $260 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Guggenheim
NULL -> Buy
maintain
$250 -> $275
2026-01-05
Reason
Guggenheim
Price Target
$250 -> $275
2026-01-05
maintain
NULL -> Buy
Reason
Guggenheim raised the firm's price target on Danaher to $275 from $250 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DHR
Unlock Now
Evercore ISI
Vijay Kumar
Outperform
maintain
$245 -> $250
2026-01-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$245 -> $250
2026-01-05
maintain
Outperform
Reason
Evercore ISI analyst Vijay Kumar raised the firm's price target on Danaher to $250 from $245 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
BofA
Buy
maintain
$250 -> $265
2025-12-15
Reason
BofA
Price Target
$250 -> $265
2025-12-15
maintain
Buy
Reason
BofA raised the firm's price target on Danaher to $265 from $250 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
